Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pfizer forecasts FY 2025 total revenues between $61 billion and $64 billion, with newly acquired drugs filling the gap for lagging COVID products such as Paxlovid. Oncology sales, which comprise ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...